Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: A systematic review and meta-analysis.

Published in: Medicine (2021)

This analysis indicated that CD109 expression could be used as a prognostic biomarker in cancer patients. This is the first meta-analysis to report the relationship between CD109 expression and prognosis in cancer patients.

Keyphrases

poor prognosis
systematic review
binding protein
long non coding rna
randomized controlled trial
meta analyses